NOVO NORDISK A S(NVO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,463 of 2,961 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
NVO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for NOVO NORDISK A S (NVO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NVO at 52.3/100 on a 32-signal composite quality model, placing it at rank #1,463 of 2,961 stocks — the top half of the AI-ranked universe. Top institutional holders of NVO by reported 13-F value include DODGE & COX, LOOMIS SAYLES & L P, FRANKLIN RESOURCES, based on the most recent SEC filings. NVO trades on the NYSE exchange and files with the SEC under CIK 353278. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NOVO NORDISK A S directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+6.4% YoYTotal Assets
+16.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $309.06B +6.4% | $290.40B +25.0% | $232.26B +31.3% | $176.95B +25.7% | $140.80B +10.9% | $126.95B |
| Total Assets | $542.90B +16.6% | $465.63B +48.1% | $314.49B +30.4% | $241.26B +24.0% | $194.51B +34.2% | $144.92B |
AI Insight: NVO Financial Trends
Equity base has nearly quadrupled since Q4 2018, driven by sustained profit retention and balance-sheet strengthening.
• Equity grew from $51.8B (Q4 2018) to $194.0B (Q4 2025), a 3.7× increase over seven years.
• Acceleration evident in recent years: equity rose $36.5B from Q4 2023 to Q4 2024, then $50.6B to Q4 2025.
⚠ Income statement and cash flow data absent; cannot assess margin quality, profitability trends, or cash generation driving equity growth.
AI Insight: NVO Ratio Trends
Insufficient data to assess Novo Nordisk's financial trends — all ratio fields are blank across the entire dataset.
• No operating margin, net profit margin, ROE, ROA, ROIC, or leverage data available for analysis.
⚠ Data completeness issue prevents evaluation of operational efficiency, profitability, and capital structure trends.
Get alerted when NVO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NOVO NORDISK A S including:
Top Institutional Holders of NVO
DODGE & COX
$977.8M20,397,110 shLOOMIS SAYLES & CO L P
$891.4M18,594,352 shFRANKLIN RESOURCES INC
$625.2M13,041,109 shPeakShares LLC
$606.1M12,642 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$575.7M12,009,200 shPRICE T ROWE ASSOCIATES INC /MD/
$561.1M11,704,719 shMORGAN STANLEY
$559.0M11,659,869 shBANK OF AMERICA CORP /DE/
$535.8M11,176,712 shCapital International Investors
$467.6M9,721,180 shFOLKETRYGDFONDET
$456.5M9,522,383 sh
| Fund | Value | Shares |
|---|---|---|
| DODGE & COX | $977.8M | 20,397,110 |
| LOOMIS SAYLES & CO L P | $891.4M | 18,594,352 |
| FRANKLIN RESOURCES INC | $625.2M | 13,041,109 |
| PeakShares LLC | $606.1M | 12,642 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $575.7M | 12,009,200 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $561.1M | 11,704,719 |
| MORGAN STANLEY | $559.0M | 11,659,869 |
| BANK OF AMERICA CORP /DE/ | $535.8M | 11,176,712 |
| Capital International Investors | $467.6M | 9,721,180 |
| FOLKETRYGDFONDET | $456.5M | 9,522,383 |
Companies Similar to NVO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ASTRAZENECA PLC
UNILEVER PLC
UNITEDHEALTH GROUP INC
Zoetis Inc.
BRISTOL MYERS SQUIBB CO
SMITH & NEPHEW PLC
GSK plc
ABBOTT LABORATORIES
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put NVO on your watchlist
Track score changes the day NOVO NORDISK A S files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NVO a good stock to buy?
13F Pro's AI-powered analysis of NOVO NORDISK A S (NVO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NVO are available on the NVO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NVO is classified as a mega company.
Which hedge funds own NVO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NVO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NOVO NORDISK A S's investment landscape.